stockrowIDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
Follow IDXX
Alert me
IDEXX Laboratories, Inc. (IDXX) EBITDA
IDEXX Laboratories, Inc.'s EBITDA for fiscal 2025 was $1.5B, up 19.6% from $1.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.7B. Over the past ten years it has ranged from $370.3M (fiscal 2015) to $1.5B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 7th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.5B | 19.63% |
| FY2024 | $1.3B | 3.81% |
| FY2023 | $1.2B | 19.92% |
| FY2022 | $1.0B | (2.50%) |
| FY2021 | $1.0B | 31.13% |
| FY2020 | $790.5M | 23.35% |
| FY2019 | $640.9M | 11.55% |
| FY2018 | $574.5M | 15.79% |
| FY2017 | $496.2M | 15.58% |
| FY2016 | $429.3M | 15.93% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $442.9M | (5.08%) |
| Jun 2026 | $466.6M | 16.58% |
| Mar 2026 | $400.3M | 12.97% |
| Dec 2025 | $354.3M | (9.49%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.5B |
| DGX Quest Diagnostics Incorporated compare | $2.3B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. | $1.7B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IDXX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement